Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 502

1.

Big pharma and health care: unsolvable conflict of interests between private enterprise and public health.

Brezis M.

Isr J Psychiatry Relat Sci. 2008;45(2):83-9; discussion 90-4. Review.

2.

Guidelines, editors, pharma and the biological paradigm shift.

Singh AR, Singh SA.

Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.

3.

Conflicts of interest in research involving human beings.

Greco D, Diniz NM.

J Int Bioethique. 2008 Mar-Jun;19(1-2):143-54, 202-3. Review.

PMID:
18664007
4.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
5.

Taking behavioralism seriously: some evidence of market manipulation.

Hanson JD, Kysar DA.

Harv Law Rev. 1999 May;112(7):1420-572.

PMID:
10558427
6.

Social marketing for public health.

Walsh DC, Rudd RE, Moeykens BA, Moloney TW.

Health Aff (Millwood). 1993 Summer;12(2):104-19.

7.

Sponsorship of physical activity programs by the sweetened beverages industry: public health or public relations?

Gómez L, Jacoby E, Ibarra L, Lucumí D, Hernandez A, Parra D, Florindo A, Hallal P.

Rev Saude Publica. 2011 Apr;45(2):423-7. Epub 2011 Jan 21. English, Spanish.

8.

The connection between academia and industry.

Singh A, Singh S.

Mens Sana Monogr. 2005 Mar;3(1):5-35. doi: 10.4103/0973-1229.27876.

9.

The politics of lead toxicology and the devastating consequences for children.

Rosner D, Markowitz G.

Am J Ind Med. 2007 Oct;50(10):740-56.

PMID:
17486583
10.

Private enterprise and public good: ethical issues in the funding of clinical research.

Williams AH, Rowell M.

Ann R Coll Physicians Surg Can. 1999 Jun;32(4):227-31.

PMID:
12385289
11.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. German.

PMID:
19034813
12.

Who is buying bioethics research?

Sharp RR, Scott AL, Landy DC, Kicklighter LA.

Am J Bioeth. 2008 Aug;8(8):54-8; discussion W1-2. doi: 10.1080/15265160802317982.

PMID:
18802867
13.

The ADVANTAGE seeding trial: a review of internal documents.

Hill KP, Ross JS, Egilman DS, Krumholz HM.

Ann Intern Med. 2008 Aug 19;149(4):251-8. Review.

PMID:
18711155
14.

Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.

Mintzes B, Barer M, Lexchin J, Bassett KL.

Res Social Adm Pharm. 2005 Jun;1(2):310-30.

PMID:
17138480
15.
16.

Alcohol research and the alcoholic beverage industry: issues, concerns and conflicts of interest.

Babor TF.

Addiction. 2009 Feb;104 Suppl 1:34-47. doi: 10.1111/j.1360-0443.2008.02433.x.

PMID:
19133913
17.

The economics of pediatric formulation development for off-patent drugs.

Milne CP, Bruss JB.

Clin Ther. 2008 Nov;30(11):2133-45. doi: 10.1016/j.clinthera.2008.11.019. Review.

PMID:
19108801
18.
19.

Where are clinical trials going? Society and clinical trials.

Sleight P.

J Intern Med. 2004 Feb;255(2):151-8. Review.

20.

Conflicts of interest in drug development: the practices of Merck & Co., Inc.

Hirsch LJ.

Sci Eng Ethics. 2002 Jul;8(3):429-42. Review.

PMID:
12353373

Supplemental Content

Support Center